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Accepted 27 March 2015; Published online 2 April 2015AbstractObjectives: Between-study heterogeneity plays an important role in random-effects models for meta-analysis. Most clinical trials are
small, and small trials are often associated with larger effect sizes. We empirically evaluated whether there is also a relationship between
trial size and heterogeneity (t).
Study Design and Setting: We selected the first meta-analysis per intervention review of the Cochrane Database of Systematic Re-
views Issues 2009e2013 with a dichotomous (n 5 2,009) or continuous (n 5 1,254) outcome. The association between estimated t
and trial size was evaluated across meta-analyses using regression and within meta-analyses using a Bayesian approach. Small trials were
predefined as those having standard errors (SEs) over 0.2 standardized effects.
Results: Most meta-analyses were based on few (median 4) trials. Within the same meta-analysis, the small study tS
2 was larger than
the large-study tL
2 [average ratio 2.11; 95% credible interval (1.05, 3.87) for dichotomous and 3.11 (2.00, 4.78) for continuous meta-
analyses]. The imprecision of tS was larger than of tL: median SE 0.39 vs. 0.20 for dichotomous and 0.22 vs. 0.13 for continuous
small-study and large-study meta-analyses.
Conclusion: Heterogeneity between small studies is larger than between larger studies. The large imprecision with which t is estimated
in a typical small-studies’ meta-analysis is another reason for concern, and sensitivity analyses are recommended.  2015 Elsevier Inc.
All rights reserved.
Keywords: Randomized controlled trial; Meta-analysis; Between-study heterogeneity; Random-effects model; Trial size; Cochrane Database of systematic
reviews (CDSR)1. Introduction
In clinical research, many small and possibly underpow-
ered studies are conducted. Among interventional trials
registered between 2007 and 2010 in ClinicalTrials.gov,
62% (17,726 of 28,458) enrolled at most 100 participants
[1]. In 2008, 70% (10,492 of 14,886) of the meta-
analyses with a binary outcome in the Cochrane Database
of Systematic Reviews (CDSR), Issue 1, consisted onlyFunding: This study was not supported by any company or grants. The
costs were borne by the authors’ institutions.
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E-mail address: joanna.inthout@radboudumc.nl (J. IntHout).
http://dx.doi.org/10.1016/j.jclinepi.2015.03.017
0895-4356/ 2015 Elsevier Inc. All rights reserved.of studies with less than 50% power to detect a 30% rela-
tive risk reduction [2].
There is an ongoing debate on the disadvantages of small
trials [3]. Small trials are associated with larger treatment ef-
fect estimates [2,4,5], and it is possible that between-study
heterogeneity also increases when studies are smaller. Turner
et al. [2] observed that removing the underpowered (!50%
power) studies from 1,107 meta-analyses resulted in a me-
dian 21% decrease in the estimated t2. Borm and Donders
[6] observed higher heterogeneity between small rheumatoid
arthritis studies compared with larger studies. Individual
study results are influenced by many, possibly related as-
pects, such as quality of study, publication bias, and study
size [7e10]. Califf et al. [1] observed that small trials contain
significant heterogeneity in methodological approaches,
including reported use of randomization, blinding, and data
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Key findings
 In a sample of 2,009 meta-analyses with a dichot-
omous outcome and 1,254 meta-analyses with a
continuous outcome of the Cochrane Database of
Systematic Reviews Issues 2009e2013, the
between-study heterogeneity t was often estimated
to be either zero or high, and the imprecision of the
estimated t was large, especially for meta-analyses
based on few and/or small studies.
 Small studies had higher mean heterogeneity esti-
mates than medium/large studies of the same
meta-analysis.
What this adds to what was known?
 Evidence from small studies tends to show not only
larger effect sizes but also larger and less precise
estimates of between-study heterogeneity.
What is the implication and what should change
now?
 In a random-effects meta-analysis, the estimated
between-study heterogeneity directly affects the
summary treatment effect and prediction interval.
It should be realized that the estimated t is often
imprecise and on average larger for small studies.
Sensitivity analyses to check robustness of the
pooled effect estimate may be warranted.
J. IntHout et al. / Journal of Clinmonitoring committees. Button et al. [11] argued that un-
derpowered studies are prone to several analytical and re-
porting biases. Small studies may be of lower quality in
other aspects of their design as well. This may affect the
between-study heterogeneity.
The current paradigm, in which multiple small studies
are conducted and subsequently combined in a meta-
analysis, is questioned [3,12]. Especially in random-
effects models and with substantial heterogeneity, the
influence of small studies will be major and may affect
the reliability of meta-analyses. On the other hand, simula-
tions have shown that a meta-analysis containing many,
possibly small, studies is better than a single large trial able
to estimate the treatment effect [6,13,14], even when there
is some publication bias [15]. Roloff et al. [16] showed that
in case of cumulative meta-analysis, it is more powerful to
add several small studies than one or a few large studies
because the between-study heterogeneity can be estimated
more precisely when more studies, either small or large,
are available. However, a questionable assumption underly-
ing their calculations is that heterogeneity is similar
between small and large studies. The same questionableassumption occurs in standard applications of random-
effects meta-analysis: one single t2 is used in the
random-effects weights for all studies.
If there is heterogeneity, treatment effects in individual
studies may deviate more from the summary effect than ex-
pected by chance. Simulations have shown that when there
is heterogeneity but no true treatment effect, the frequency
of false statistically significant findings in single trials in-
creases more than 10-fold [15]. When small studies have
higher than average heterogeneity, the increase in error
rates for small single trials will be even larger. Also, predic-
tion intervals [17] constructed with an average t will result
in too narrow predictions for the expected effect for future
small trials.
In summary, if there is a difference in heterogeneity
between small and large trials, this can influence both the
reliability of the results of single trials and of meta-
analyses. Results of the current method for random-
effects meta-analysis may be overly drawn toward the
small-study results, prediction intervals may be too narrow,
and false-positive findings of single trials may occur more
frequently than expected.
In this article, we investigate empirically whether the
heterogeneity of small and large trials is different. We
used meta-analyses from 3,851 reviews on interventions
of the 2009e2013 Issues from the CDSR. First, we
investigated in a cross-sectional approach the relation be-
tween study size and heterogeneity across 3,263 meta-
analyses. As Turner et al. [18] showed that the extent
of heterogeneity could be related to outcome and inter-
vention type, our primary analysis is a paired-data
approach, comparing the between-study heterogeneity of
large trials with the small-study heterogeneity of the
same meta-analysis.2. Methods
2.1. Selected data
The UK Cochrane Editorial Unit provided us with the
statistical data of the systematic reviews of interventions,
included in the CDSR Issues of 2009e2013. We used the
mean values and standard deviations per treatment group
for meta-analyses with continuous outcomes and counts
(with/without event) for those with dichotomous outcomes.
Most Cochrane reviews included multiple meta-analyses,
and meta-analyses from the same review are often corre-
lated. The first reported analysis in a review is usually
one of the primary analyses. Hence, to avoid subjectivity
in selecting specific meta-analyses, we used only the first
meta-analysis appearing in the data and analyses section
that was based on at least two studies. To maximize the
number of meta-analyses for our evaluation, we used both
the first continuous and the first binary outcome meta-
analysis, if available. A selected meta-analysis could
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mutually exclusive, for example, when subgroup analyses
were done and the same individuals were used in more than
one subgroup. If the subanalyses were combined and re-
sulted in a summary effect size in the original review, we
also combined the subgroups. Otherwise, we selected the
subgroup analysis based on the largest number of studies.2.2. Estimation of heterogeneity
Heterogeneity can be expressed as the between-study
variance t2, with t in the same unit as the meta-analysis
outcome, or as a relative measure I2, the relative degree of
inconsistency across studies [19,20]. We focused on t2,
because in the random-effects analysis [21] and also in the
reliability of the results of a single trial [13], t2 plays a direct
role as opposed to I2,whichdeven if t2 remains the samedis
expected to increase with increasing sample sizes of the
studies: E(I2) 5 t2/(t2þs2), where s2 is the typical within-
study variance [19]. Furthermore, the relation between I2
and sample size already has been investigated by others
[22,23].We used the empirical Bayes estimator for t2, equiv-
alent [24] to the robust [25] Paule and Mandel [25e27] esti-
mator and more accurate than the widely used Method of
Moments estimator of DerSimonian and Laird (DL)
[21,28], which is based on large sample assumptions [27].
Furthermore, the relative bias is similar for small to large het-
erogeneity, as opposed to the DL and restricted maximum
likelihood estimators, that underestimate t2 more as the het-
erogeneity increases, especially for dichotomous outcomes
[25,28]. We estimated t2 for all meta-analyses, even when
the authors originally performed a fixed-effects analysis.
Regression analyses were done with t, because t2 has a very
skewed distribution. The paired comparisons between het-
erogeneity in large- and small-study meta-analyses (Section
2.5) were based on Bayesian estimates of t.
To remove unnecessary variation in the outcomes, contin-
uous outcomes were analyzed as standardized mean differ-
ences (SMDs). Dichotomous outcomes were analyzed as
log odds ratios (ORs), where log represents the natural loga-
rithm. If no events were observed in one or both arms, we
added 0.5 to all cells of such a study before we estimated
the heterogeneity. Adding 0.5 will slightly move the treat-
ment effect to nil and decrease the between-study heteroge-
neity [29]. As small studies more often have zero events
than large studies, this is a conservative approach. Effect
sizes were tuned, that is, to give all meta-analyses a positive
summary effect (SMDO 0 or ORO 1), the treatment groups
in a meta-analysis were switched if needed. Pooled effect
sizes, t2 estimates, and its standard errors (SEs) resulted from
meta-analyses performed with the metafor package version
1.9-2 [30], R software (Vienna, Austria) [31] version 3.0.1.
The Bayesian approach was carried out using WinBUGs
(Cambridge, UK) version 1.4.3 [32], called from R with the
package R2WinBUGS version 2.1-19 [33]. Other statistical
analyses were performed with SAS/STAT software version9.2 for Windows, copyright 2002-2008 by SAS Institute
Inc., Cary, NC, USA.
2.3. Definition of trial size
We categorized trial size based on trial precision (1/SE
of the treatment effect). For this categorization (only), we
converted the precision of the trials with an OR outcome
into the same order of magnitude as the trials with an
SMD by multiplying the precision with p/O3 5 1.81
[34]. Trials were a priori categorized as very small
(size ! 3), small (3  size ! 5), medium sized
(5  size ! 7.5), or large (size  7.5). The cutoff size
for separating very small/small trials from medium/large
trials was set at 5, corresponding to an SE of 0.2 standard-
ized effects.
2.4. Heterogeneity and trial sizedacross meta-analyses
We categorized the (geometric) mean trial size per meta-
analysis in the same way as the trial size (Section 2.3).
Grouped by mean trial size, the estimated t was cross-
tabulated in three categories (0, 0e0.5, andO0.5), and me-
dians and interquartile ranges (25the75th percentile, i.e.,
Q1eQ3) of t were presented for those meta-analyses with
an estimated t O 0. We explored the relation between t
(continuous) and mean log trial precision (1/SE) with
weighted linear regression, as the data appeared to be het-
eroscedastic. We conducted univariate regression and
multivariate regression adjusted for the log of the number
of studies and Cochrane group, where Cochrane groups
with less than seven observations were pooled in an
‘‘other’’ group. Weights were based on the SE2 of t, where
the SE(t) was estimated by taking the squared root of the
limits of the 95% confidence interval (CI) for t2, defined
as t2 6 1.96 SE, and dividing the distance between these
roots by 3.92. In addition, we explored the association be-
tween the estimated t and trial precision per Cochrane
group and also the association with other meta-analysis
characteristics (geometric mean study N, ratio of largest/
smallest study, effect size, overall precision, total number
of subjects and events, and mean event rate), adjusted for
the log of the number of studies and Cochrane group.
2.5. Heterogeneity and trial sizeepaired analyses
An analysis of the association between heterogeneity
and trial size across meta-analyses may be hampered by
confounders. For example, the endpoint of the analysis
may have an impact on both the heterogeneity and the study
precision [2,18]. Hence, an apparent relationship between
heterogeneity and trial size may be solely the result of dif-
ferences in endpoints across meta-analyses. A comparison
of the heterogeneity of the largest studies vs. heterogeneity
of the smallest studies of the same meta-analysis is less
prone to confounding. Therefore, we also investigated the
association between trial size (defined as in Section 2.3)
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advantage that the results are matched, that is, controlled
for outcome. In the paired analyses, small studies, catego-
rized as having very low or low size (!5), were compared
with large studies, that is, medium or high size (5). In
sensitivity analyses, we restricted the comparison to the
very small (!3) vs. large trials (7.5). We selected
meta-analyses that contained at least two trials of each type,
that is, at least two smaller and two larger trials and
compared the heterogeneity between the larger studies with
the heterogeneity between the smaller studies. If more
studies were available, those were also used in the paired
comparison because heterogeneity estimates are more pre-
cise when they are based on larger and/or more studies [35].
In addition to several other characteristics,weestimatedper
meta-analysis the heterogeneity tS for the selected small
studies and in a similarway tL of the selected large studies. Ef-
fect sizes were tuned, that is, to give the mean of the large-
study and small-studymeta-analysis a positive summary effect
(SMDO 0 orORO 1), the treatment groupswere switched if
needed. Results were summarized with medians and Q1eQ3.
To compare tS and tL, while incorporating the imprecision of
the heterogeneity estimateswe used aBayesian approach. The
ratiobetween the small studytS vs. thetLof the corresponding
larger-study meta-analysis was estimated with Markov Chain
Monte Carlo (MCMC) procedures in WinBUGS, using a
bivariate lognormal distribution fortS andtL.The information
contained in the posterior distributions for the mean ratio and
the tS and tL was summarized bymeans and Bayesian (equal-
tail) 95%credible intervals (CrI) and indicativeP-values based
on the percentage of times that the mean ratio of tS vs. tL was
1. For the MCMC procedures, we took 200,000 iterations
with 50,000 for burn-in and thinning 1 per 100. We checked
that theMCMC procedures had reached convergence by visu-
ally inspecting the history trace plots, the autocorrelationplots,
and the cumulative quantile plots for irregularities. The Win-
BUGS syntax of our model is provided in Table S1/
Appendix at www.jclinepi.com.3. Results
3.1. Selected meta-analyses
In total, 3,851 reviews were retrieved from the CDSR Is-
sues of 2009e2013 (Fig. 1). Selection of reviews containing
a meta-analysis with a dichotomous or continuous outcome
and based on at least two studies resulted in 2,309 reviews:
2,009 contain at least one meta-analysis with a dichotomous
outcome and 1,254 at least one with a continuous outcome
that could be used for the across-reviews analyses.
Most meta-analyses were based on a few small studies.
Of the 3,263 selected meta-analyses, 1,025 (31%) were
based on 2 studies, 1,226 (38%) on 3 to 5 studies, 603
(18%) on 6 to 10 studies, and 409 (13%) on more than
10 studies. The median number of studies per meta-
analysis was 4 (Q1eQ3: 2e6), and most of the studies weresmall: overall, of the 20,185, trials 14,985 (74%) were very
small (45%) or small (29%), and only 5,200 (26%) were
categorized as larger: 14% as medium sized and 11% as
large. Meta-analyses with a dichotomous outcome had a
lower average study precision (1/SE) than those with a
continuous outcome (median 1.5; Q1eQ3: 1e2.3 vs. 4.0;
Q1eQ3: 3.1e5.3). The number of very small and small tri-
als was also higher for the meta-analyses with a dichoto-
mous outcome: 79% vs. 66% for those with a continuous
outcome. The median estimated t2 was 0 (Q1eQ3:
0e0.17) for the meta-analyses with a dichotomous outcome
and 0.03 (Q1eQ3: 0e0.21) for those with a continuous
outcome. More details of the selected meta-analyses are
presented in Table 1.
The total number of Cochrane Groups present in our se-
lection is 52. The Pregnancy and Childbirth Group pro-
vided by far most meta-analyses: 229 (11%) with a
dichotomous and 135 (11%) with a continuous outcome.
An overview of the Cochrane Groups including estimated
heterogeneity and study precision can be found in Table
S2/Appendix at www.jclinepi.com.3.2. Heterogeneity vs. study sizeeacross meta-analyses
In 1,559 (48%) of the 3,263 selected meta-analyses, the
estimated heterogeneity was 0. This percentage was higher
for the meta-analyses with a dichotomous than with a
continuous outcome: 55% vs. 36%.
Fig. 2 shows the estimated t in relation to the mean
study precision. The percentages in Table 2 suggest that
in small studies, the estimated t is more often either equal
to zero or larger than 0.5. For larger studies, t seems more
of moderate size, that is, between 0 and 0.5. For example,
the percentage of dichotomous outcome meta-analyses with
a moderate t increased from 13% for meta-analyses with
on average very small studies to 40% for meta-analyses
of large studies. A similar increase, from 24% to 59%, is
seen for the meta-analyses with a continuous outcome.
The number of zero and large t estimates decreased corre-
spondingly. This pattern is also observed in the meta-
analyses with an estimated t O 0.
The estimated t was negatively associated with the
mean study precision according to the univariate regression
(Table 2), which suggests that small studies on average may
have larger between-study heterogeneity. For the meta-
analyses with a dichotomous outcome, the negative associ-
ation was no longer significant after adjustment for log
number of trials and Cochrane Group, whereas for those
with a continuous outcome it was.
Most meta-analysis characteristics were much stronger
associated with the estimated t than the study precision.
The increase in model R2 due to study precision was only
1% and 3% for the meta-analyses with a dichotomous and
continuous outcome, respectively, compared with a model
with only the Cochrane Group and log number of studies.
Not surprisingly, the precision of the meta-analysis effect
CDSR 2009-2013
3,851 SRs
SRs with continuous or dichotomous MA ≥ 2 studies
2,309 SRs; 40,046 MAs
Dichotomous
2009 SRs;  28,635 MAs 
164,285 studies
Excluded:
N= 1542 SRs
2,009 independent MAs
13,116 studies
Continuous
1,254 SRs;  11,411 MAs, 
59,306 studies
1,254 independent MAs
7,069 studies
360 pairs of  MAs
1790 M/L  vs. 3324  VS/S studies
235 pairs of  MAs
1427 M/L  vs. 1964 VS/S studies
43 pairs of MAs
297 L  vs. 345 VS studies
Excluded:
441 MAs with 
less than 2 VS 
and L studies111 pairs of MAs
488 L  vs. 844 VS studies
Across-MA
analyses
Paired
analyses
Sensitivity
analyses
Excluded:
36,783 MAs 
that  were  not
first MA of SR
Fig. 1. Flowchart of selection and analysis. CDSR 2009-2013, Issues of the Cochrane Database of Systematic Reviews of 2009e2013; SR, sys-
tematic review; MA, meta-analysis; VS, very small; S, small; M, medium sized; L large.
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model R2 of 39% and 43%, respectively. The meta-analysis
effect size showed the second largest increase in R2 (10%
and 14%, respectively), see Table S3/Appendix at www.
jclinepi.com.3.3. Trial size vs. heterogeneityepaired analyses
The 2,009 series of trials with a dichotomous outcome re-
sulted in 360 pairs of at least two large and two small trials;
the 1,254 series with a continuous outcome in 235 pairs.
Table 3 shows the characteristics of the pairs. We foundTable 1. Characteristics of the selected meta-analyses
Median (Q1eQ3)
MAs with dichotomous ou
(N [ 2,009)
MA effect size (OR/SMD) 1.64 (1.21e2.61
Precision (1/SE) MA effect size 4.3 (2.4e7.7)
Total number of studies 13,116
Total number of small studiesa (%) 10,331 (79)
Number of studies per MA 4 (2e7)
Number of small studies per MAa 3 (2e6)
Study precision (1/SE)b per MA 1.5 (1.0e2.3)
Study Nb per MA 99 (58e202)
Ratio of largest/smallest study per MA 4.3 (2.0e11.3)
Number of subjects per MA 575 (237e1,60
Number of events per MA 114 (40e343)
Mean event rate per MA 0.21 (0.08e0.44
Estimated t 0 (0e0.41)
Estimated t2 0 (0e0.17)
I2 (%) 0 (0e43.1)
Abbreviations: MA, meta-analysis; OR, odds ratio; SMD, standardized m
Data are summarized with median and interquartile range (Q1eQ3).
a Small studies contain the very small studies (size !3) and the small
b Geometric mean.somewhat larger effect sizes for the meta-analyses based on
small trials than on large trials, both for the dichotomous
and the continuous outcomes. The imprecision (SE) of the t
estimates was higher for the small-study meta-analyses
comparedwith the large-studymeta-analyses andmuchhigher
for themeta-analyses based onvery small studies. The number
of meta-analyses where t was estimated to be zero was high,
especially in the very small/small-study meta-analyses with
a dichotomous outcome: 53%,comparedwith 42%for the cor-
responding pairs of medium/large-study meta-analyses and
30% vs. 29% for the continuous outcome meta-analyses.
The occurrence of t O 0.5 estimates also differed betweentcome MAs with continuous
outcome (N [ 1,254)
All MAs
(N [ 3,263)
) 0.31 (0.14e0.62) NA
7.0 (3.8e13.0) 5.1 (2.7e9.6)
7,069 20,185
4,654 (66) 14,985 (74)
3 (2e6) 4 (2e6)
2 (1e4) 3 (2e5)
4.0 (3.1e5.3) 2.4 (1.3e4.0)
67 (41e119) 85 (50e164)
3.1 (1.7e7.0) 3.7 (1.9e9.3)
7) 298 (134e700) 432 (186e1,263)
NA NA
) NA NA
0.16 (0e0.46) 0.07 (0e0.43)
0.03 (0e0.21) 0 (0e0.18)
39.3 (0e77.3) 4.8 (0e58.9)
ean difference; SE, standard error; NA, not applicable.
studies (size !5), see Section 2.3 for the definition of size.
Fig. 2. Estimated heterogeneity (t) vs. trial precision across meta-analyses. Left: meta-analyses with a dichotomous outcome; right: meta-analyses
with a continuous outcome. Mean study precision is the geometric mean of the precisions (1/SE) of the studies in a meta-analysis. Black dots
correspond to meta-analyses with the 25% largest weights in the weighted regression, that is, the 25% t estimated most precisely. SE, standard
error.
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25% vs. 11% for the meta-analyses with a dichotomous and
31% vs. 9% for those with a continuous outcome. Overall,
the estimated tS was larger than tL, with point estimates ofTable 2. Estimated t in relation to study precision across meta-analyses
Outcome Very small
MAs with dichotomous outcome (N 5 2,009)
Overall 1,108
Estimated t [n (%)]
t 5 0 731 (66)
0 ! t  0.5 144 (13)
t O 0.5 233 (21)
Estimated t if O0
N (MAs with estimated t O 0) 377
Median t 0.64
Q1eQ3 0.37e1.03
P90 1.58
Linear regressionb
Unadjusted slope 0.041,
Adjusted slope 0.013,
MAs with continuous outcome (N 5 1,254)
Overall 282
Estimated t [n (%)]
t 5 0 112 (40)
0 ! t  0.5 68 (24)
t O 0.5 102 (36)
Estimated t if O0
N (MAs with estimated t O 0) 170
Median t 0.65
Q1eQ3 0.36e1.23
P90 1.81
Linear regressionb
Unadjusted slope 0.096,
Adjusted slope 0.072,
Abbreviations: MA, meta-analysis; Q1eQ3, 25th and 75th percentile
interval.
a Based on geometric mean study size per MA (Section 2.4).
b Results of weighted linear regression with estimated t as dependent an
adjusted for log number of studies and Cochrane group.0.22 vs. 0.15 and 0.27 vs. 0.15 and estimated mean ratios for
t2S/t
2
L of 2.11 (95%CrI: 1.05, 3.87) for the meta-analyses with
a dichotomous and 3.11 (95%CrI: 2.00, 4.78) for those with a
continuous outcome.Mean study size per MAa
Small Medium Large
580 214 107
255 (44) 73 (34) 50 (47)
196 (34) 109 (51) 43 (40)
129 (22) 32 (15) 14 (13)
325 141 57
0.43 0.31 0.27
0.29e0.65 0.19e0.46 0.15e0.46
0.96 0.69 0.73
95% CI (0.055, 0.028) P ! 0.001
95% CI (0.028, 0.001) P 5 0.078
603 246 123
209 (35) 86 (35) 43 (35)
245 (41) 127 (52) 73 (59)
149 (25) 33 (13) 7 (6)
394 160 80
0.38 0.21 0.12
0.23e0.65 0.12e0.41 0.08e0.24
1.01 0.78 0.47
95% CI (0.113, 0.078) P ! 0.001
95% CI (0.091, 0.052) P ! 0.001
of distribution; P90, 90th percentile of distribution; CI, confidence
d mean log study precision as independent variable, unadjusted, and
Table 3. Heterogeneity vs. trial sizeepaired comparisons
Trial size
All meta-analyses Very small-study vs. large-studyebased meta-analyses
Dichotomous Continuous Dichotomous Continuous
VS/small Medium/large VS/small Medium/large Very small Large Very small Large
Median (Q1eQ3)
N 360 360 235 235 111 111 43 43
No of
studies
6 (3e11) 3 (2e5) 5 (3e9) 3 (2e7) 4 (2e9) 3 (2e5) 3 (2e6) 5 (2e7)
Precision
(1/SE)a
1.5 (1.2e1.8) 3.9 (3.5e4.7) 3.5 (3.1e3.9) 6.9 (6.0e7.9) 1 (0.8e1.2) 5.6 (5.0e7.1) 2.5 (2.2e2.6) 9.8 (8.8e10.7)
Study Nb 93 (67e146) 397 (262e734) 52 (41e66) 195 (151e261) 79 (50e146) 985 (570e2043) 28 (23e33) 403 (323e512)
No of
subjects
694 (342e16,301) 1,646 (839e4,190) 284 (164e518) 799 (390e2,184) 431 (216e1,233) 3,519 (1901e8,407) 107 (59e332) 1921 (1,294e4,007)
Effect sizec
(OR/SMD)
1.72 (1.24e2.53) 1.29 (1.10e1.71) 0.40 (0.20e0.68) 0.20 (0.10e0.38) 1.98 (1.39e3.59) 1.24 (1.05e1.49) 0.95 (0.46e1.43) 0.31 (0.13e0.42)
No of events 125 (62e241) 412 (241e956) 42 (24e102) 763 (465e1,793)
Mean event
rate
0.20 (0.08e0.42) 0.29 (0.13e0.46) 0.11 (0.04e0.32) 0.20 (0.11e0.41)
t 50d
[n (%)]
190 (53) 152 (42) 71 (30) 69 (29) 74 (67) 45 (41) 11 (26) 11 (26)
t O0.5d
[n (%)]
90 (25) 40 (11) 73 (31) 20 (9) 29 (26) 7 (6) 25 (58) 5 (12)
SE(t)d 0.39 (0.31e0.52) 0.20 (0.15e0.28) 0.22 (0.18e0.35) 0.13 (0.09e0.20) 0.61 (0.52, 0.79) 0.14 (0.11e0.20) 0.46 (0.30e0.83) 0.11 (0.07e0.19)
Comparison of tS with tL
e
N 360 235 111 43
t [mean
(95% CrI)]
0.22 (0.16, 0.28) 0.15 (0.12, 0.18) 0.27 (0.22, 0.32) 0.15 (0.13, 0.17) 0.02 (0, 0.15) 0.11 (0.07, 0.15) 0.50 (0.31, 0.71) 0.18 (0.14, 0.22)
tS/tL [mean
(95% CrI)]
1.45 (1.02, 1.97), P 5 0.02 1.76 (1.41, 2.19), P ! 0.001 0.17 (0.00, 1.50), P 5 0.91 2.80 (1.66, 4.25), P ! 0.001
t2S/t
2
L [mean
(95% CrI)]
2.11 (1.05, 3.87), P 5 0.02 3.11 (2.00, 4.78), P ! 0.001 0.03 (0.00, 2.23), P 5 0.91 7.82 (2.76, 18.03), P ! 0.001
Abbreviations: Q1eQ3, interquartile range, with 25th and 75th percentile of distribution; SE, standard error; OR, odds ratio; SMD, standardized mean difference; CrI, credible interval; P, P-
values based on CrI, for indicative purposes.
Data are summarized with median and interquartile range (Q1eQ3), unless otherwise mentioned.
a
Precision: geometric mean precision (1/SE) of selected large or small studies in the MA.
b
Geometric mean.
c
Effect sizes were tuned such that the mean effect size per MA was O0 for SMDs and O1 for ORs.
d
Based on empirical Bayes estimates for t.
e
Based on Markov Chain Monte Carlo estimates.
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study size differences. For the meta-analyses with a dichoto-
mous outcome, the percentage of t 5 0 estimates was 67%
for the very small studies vs. 41% for the large studies,
compared with twice 26% for the very small- and large-
study meta-analyses with a continuous outcome. The occur-
rence of t O 0.5 was 26% vs. 6% for the very small- and
large-study dichotomous and 58%vs. 12% for the continuous
outcomemeta-analyses. For themeta-analyses with a contin-
uous outcome, the mean ratio t2S/t
2
L was again confidently
larger than 1 (7.28, 95% CrI: 2.76, 18.03), but for those with
a dichotomous outcome, the point estimate was smaller than
1 and theCrI contained the 1 (0.03, 95%CrI: 0.00, 2.23). Pos-
terior distributions of the mean heterogeneity (tS and tL) are
presented in Fig. 3.
4. Discussion
In a random-effects meta-analysis, both the treatment ef-
fects of the individual studies and the between-study hetero-
geneity play an important role. Small trials are associated
with larger effect sizes than large trials. In absence of publi-
cation bias, sample size in itself does not bias the outcome ofa study [36]. However, there are several reasons why small
trials may also have a different level of heterogeneity than
larger trials. Only after promising results of the initial, small
exploratory trials, larger trials tend to be conducted, possibly
in different patient populations [4,12,37]. On the other hand,
small trials may suffer from lower-quality standards and
show a diminished effect [38]. These opposite patterns may
cause increased heterogeneity [20], which can only be stud-
ied with empirical data.
Using over 3,000 first meta-analyses from the CDSR Is-
sues 2009e2013, we have investigated whether there is a
relationship between study size and heterogeneity. Most
meta-analyses were based on few studies (median 4;
Q1eQ3: 2e6). On average, the estimated t weakly
decreased when precision was larger. To minimize effects
of outcome and intervention type [18], we performed paired
analyses, comparing heterogeneity from the smaller with the
larger studies originating from the same meta-analysis. The
findings show that the meta-analyses of very small/small
studies result in significantly higher mean heterogeneity esti-
mates than medium/large studies. Point estimates indicated
an estimated mean tS
2 that was at least twice as large as tL
2.
Fig. 3. Posterior distributions of the mean heterogeneity between small (tS) and large (tL) trials resulting from paired comparisons. Posterior den-
sities are obtained with WinBUGS. MAs, meta-analyses. Left column: all possible pairs (very small/small vs. medium/large studies). Right column:
pairs of very small vs. large studies.
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in a similar range as previously reported percentages of
dichotomous meta-analyses: 49% based on meta-analyses
of at least two trials [20] and 37% based on at least four
studies [39]. Meta-analyses with low precision for the sum-
mary effect, that is, based on few and/or small studies, re-
sulted more frequently in zero or high (O0.5) point
estimates for t, and the corresponding imprecision (SE)
of the estimated t was large. The high occurrence of zero
estimates may be caused by the fact that many of the
selected meta-analyses were based on a few small studies
and that sample variances for small studies are large. When
studies have equal sample variances s2, the t2 estimator
corresponds to the sum of (yiey)
2/(k-1) minus s2 [21,25],
or zero if the result is negative, where k is the number of
studies. Consequently, for imprecise studies with large s2,
the estimate of t2 will often be zero, even when the true
heterogeneity is substantial. The sample variances of the
small studies with a dichotomous outcome were larger than
those of the small studies with a continuous outcome. This
may have caused the abundance of zero t estimates in themeta-analyses with a dichotomous outcome. This may also
be the reason that the estimated mean ratio t2S/t
2
L was below
1 in the sensitivity analyses with dichotomous outcomes,
whereas the other ratios were larger than 1. Also for the pri-
mary paired comparisons of the meta-analyses with a
dichotomous outcome, the ratios were lower compared with
the ratios of the meta-analyses with a continuous outcome.
Our study has some limitations, ofwhich probably themost
important is that we had to evaluate the relation between t and
study size using the estimates of t instead of the true values.
Especially if studies are small, heterogeneity may be present
but difficult to estimate, which complicated in particular the
analyseswith the dichotomous outcomes. In the current setting
of medical interventions, most of the estimates were impre-
cise. Thiswas evenmore the case in the paired analyses,where
wehave split the originalmeta-analyses in a large- and a small-
study part. For a stable estimate of I2, approximately 500
events and 15 studies are needed [40], and the same may be
true for t. But if we had restricted our analyses to meta-
analyses with 15 or more studies, the randomness of the sam-
ple would have become questionable. Performing the paired
868 J. IntHout et al. / Journal of Clinical Epidemiology 68 (2015) 860e869comparisons decreased our sample significantly. Therefore,
we also evaluated the relation between trial precision and het-
erogeneity across meta-analyses: this gave us the opportunity
to include all meta-analyses. A second limitation is that the set
of interventions for which a systematic review is conducted is
not random. Some reviews may have been conducted for the
very reason of conflicting results and between-study heteroge-
neity, whereas some others may have avoided meta-analyses
specifically because of high heterogeneity [41]. Furthermore,
we used both the first dichotomous and the first continuous
outcomemeta-analysis froma review if available.Our conclu-
sions with respect to the heterogeneity in meta-analyses with
continuous and dichotomous outcomes are thus not
independent.
We conclude that the between-study heterogeneity for
small studies is larger than for large studies, but often the
estimate of t is imprecise and either zero or high (O0.5).
In future research, the behavior of the estimated heteroge-
neity in the context of small studies with a dichotomous
outcome should be investigated further. When the estimate
of t2 is imprecise, we recommend sensitivity analyses to
evaluate the robustness of the estimated combined meta-
analysis effect, using various t2 values. Using models that
do not assume a common random-effects distribution
across studiesdfor example, models with different t2 esti-
mates in the weights for small and large studiesdare
another possibility, but this would be difficult to perform
in most meta-analyses, given the limited number of studies.
Regardless, the results of random-effects meta-analysis
need to be interpreted with extra caution, especially when
small studies are involved.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2015.03.017.References
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